Form 8-K IMMUNIC, INC. For: Feb 09
- Indexes jump on inflation data; Nasdaq posts best qtr since 2020
- EPS recession is coming; Citi upgrades US equities, Tech to Overweight
- Eurozone inflation slows by more than expected in March
- Micron (MU) drops as China launches cybersecurity review of its products
- Netflix to rein in movie output, slash jobs in restructuring push - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
|(Commission File Number)||(IRS Employer Identification No.)|
(Address of principal executive offices)
Registrant’s telephone number, including
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Item 8.01. Other Events
On February 9, 2023, Immunic, Inc. (the “Company”) issued a press release and presentation announcing a virtual celiac disease R&D webcast to highlight the current pathways for drug development, the current and potential treatment options and the unmet medical need for effective therapeutics. The company announced that initial results from the Part C portion of the ongoing phase 1 clinical trial of IMU-856 in celiac disease patients are expected to be available in mid-2023. The press release and presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
|99.1||Press Release, dated February 9, 2023.|
|99.2||Presentation, dated February 9, 2023.|
|104||Cover Page to this Current Report on Form 8-K in Inline XBRL|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|Dated: February 9, 2023||Immunic, Inc.|
|By:||/s/ Daniel Vitt|
|Chief Executive Officer|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- April is World Autism Month, let’s create an inclusive Canada where autistic people can reach their full potential.
- SecSee Startup Announces Launch
- Phoenix Multimedia Advertising Service Announced by Content Marketing Media
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!